David Gordon, MD
Interventional Pain Medicine · Indianapolis, INNPI 1760724603
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $17,963 of the $28,278 with a category attached, or 63.5%. 52 manufacturers reported payments, led by Boston Scientific at 31.4% of the total. Reporting peaked in 2024 at $8,587 and has fallen 69.0% since, to $2,663 in 2025. Among interventional pain medicine clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 822 payments — averaging $34.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$9K
- Medtronic$4K
- AbbVie$3K
- Abbott$2K
- Si-bone, Inc.$1K
- Biohaven Pharmaceuticals, Inc.$1K
- plus $8K from 46 others
What the payments were for
- Consulting fees$6,51323%
- Travel & lodging$3,78413%
- Food & beverage$17,96364%
- Education$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYNCHROMEDII$1,590
- WaveWriter Alpha Prime 16$1,440
- iFuse Implant$1,385
- NURTEC ODT$1,323
- Superion ISS$899
- Intracept$800
- mild Device Kit$624
- INTELLIS ADAPTIVESTIM$497
- GENERAL PAIN MANAGEMENT$367
- Proclaim IPG$351
- Neuromodulation Dspsbls and Accs$251
- UBRELVY$238
- VANTA ADAPTIVESTIM$200
- Zilretta$150
- ReActiv8$146
- Evoke$141
- INFINION$141
- Proclaim Family of SCS IPGs$132
- SPECTRA WAVEWRITER$124
- Prospera$124
How this compares
$28,278 in reported general payments places this provider in the 90th percentile of 68 interventional pain medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 123 | $99,752 |
| PercocetOxycodone Hcl/Acetaminophen | 12 | $75,633 |
| Buprenorphine | 243 | $69,278 |
| Nurtec OdtRimegepant Sulfate | 24 | $40,313 |
| Emgality PenGalcanezumab-Gnlm | 30 | $24,375 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 742 | $19,938 |
| UbrelvyUbrogepant | 16 | $17,431 |
| OxycontinOxycodone Hcl | 37 | $16,254 |
| Xtampza ErOxycodone Myristate | 36 | $15,837 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 521 | $15,195 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 95 | $14,768 |
| QuliptaAtogepant | 11 | $12,992 |
| BotoxOnabotulinumtoxina | 11 | $12,807 |
| ButransBuprenorphine | 26 | $11,029 |
| LinzessLinaclotide | 20 | $10,744 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $1,321 | $115,589159 claims |
| AbbVieUbrelvy, Qulipta, Botox, Linzess | $2,521 | $53,97558 claims |
| PfizerNurtec Odt | $55 | $40,31324 claims |
| Redhill Biopharma Inc.Movantik | $85 | $7,11718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 68 interventional pain medicine providers in Indiana.
Other interventional pain medicine in Indianapolis
- Vinayak BelamkarIndianapolis$28K
- Jocelyn BushIndianapolis$20K
- Edward KowlowitzIndianapolis$15K
- Ashley TolbertIndianapolis$15K
- Kristin GossIndianapolis$7K
- Caroline AsavaIndianapolis$3K
- Keiona WallerIndianapolis$3K
- Michael DorwartIndianapolis$3K
- Dena SeifertIndianapolis$2K
- David RatzmanIndianapolis$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.